Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 984-994

  Tuccinardi, Tiziano ^a   Ferrarini, Pier Luigi ^a   Manera, Clementina ^a   Ortore, Gabriella ^a   Saccomanni, Giuseppe ^a   Martinelli, Adriano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DOCKING PROTEIN; RECEPTOR SUBTYPE; RHODOPSIN;

ARTICLE; DRUG SELECTIVITY; HYPOTHESIS; LIGAND BINDING; MOLECULAR MODEL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; RELIABILITY; RESIDUE ANALYSIS; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ARACHIDONIC ACIDS; CATTLE; INDOLES; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MORPHOLINES; NAPHTHALENES; NAPHTHYRIDINES; POLYUNSATURATED ALKAMIDES; PROTEIN CONFORMATION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RHODOPSIN; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 32344446060     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050875u     Document Type: Article

References (58)

1. Gaoni, Y.; Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646-16477.
2. Mechoulam, R.; Ben-Shabat, S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat. Prod. Rev. 1999, 16, 131-143.
3. Breivogel, C. S.; Griffin, G.; Di Marzo, V.; Martin, B. R. Mol. Pharmacol. 2001, 60, 155-163.
4. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
5. Huffman, J. W.; Lainton, J. A. H. Recent developments in the medicinal chemistry of cannabinoids. Curr. Med. Chem. 1996, 3, 101-116.
6. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. S.; De Costa, D. R.; Rice, K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 1932-1936.
7. Pertwee, R. G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 1999, 6, 635-664.
8. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232, 54-61.
9. Recht, L. D.; Salmonsen, R.; Rosetti, R.; Jang, T.; Pipia, G.; Kubiatowski, T.; Karim, P.; Ross, A. H.; Zurier, R.; Litofsky, N. S.; Burstein S. Antitumor effects of ajulemic acid (CT3), a synthetic nonpsychoactive cannabinoid. Biochem. Pharmacol. 2001, 62, 755-763.
10. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48, 443-450.
11. Reggio, P. H. Pharmacophores for ligand recognition and activation/ inactivation of the cannabinoid receptors. Curr. Pharm. Des. 2003, 9, 1607-1633.
12. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 1998, 125, 924-947.
13. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 2000, 21, 90-113.
14. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
15. Reggio, P. H. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges. Curr. Med. Chem. 1999, 6, 665-683.
16. Song, Z. H.; Bonner, T. I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol. 1996, 49, 891-896.
17. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB1 receptor constitutes an agonist/ inverse agonist binding region. J. Med. Chem. 2003, 46, 5139-5152.
18. Song, Z. H.; Slowey, C. A.; Hurst, D. P.; Reggio, P. H. The difference between the CB1 and CB2 cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB2. Mol. Pharmacol. 1999, 56, 834-840.
19. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
20. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680.
21. McGuffin, L. J.; Bryson, K.; Jones, D. T. The PSIPRED protein structure prediction server. Bioinformatics 2000, 16, 404-405.
22. Jones, D. T.; Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol. 1999, 292, 195-202.
23. Salo, O. M.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem. 2004, 47, 3048-3057.
24. Ballesteros, J. A.; Jensen, A. D.; Liapakis, G.; Rasmussen, S. G.; Shi, L.; Gether, U.; Javitch, J. A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 2001, 276, 29171-29177.
25. Sansom, M. S.; Weinstein, H. Hinges, swivels and switches: the role of pralines in signalling via transmembrane alpha-helices. Trends Pharmacol. Sci. 2000, 21, 445-451.
26. Jensen, A. D.; Guarnieri, F.; Rasmussen, S. G.; Asmar, F.; Ballesteros, J. A.; Gether U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem. 2001, 276, 9279-9290.
27. Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ballesteros, J. A.; Javitch, J. A. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 2002, 277, 40989-40996.
28. Singh, R.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Guarnieri F. Activation of the cannabinoid CB1 receptor may involve a W6.48/F3.36 rotamer toggle switch. J. Pept. Res. 2002, 60, 357-370.
29. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thorton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
30. Tao, Q.; McAllister, S. D.; Andreassi, J.; Nowell, K. W.; Cabral, G. A.; Hurst, D. P.; Bachtel, K.; Ekman, M. C.; Reggio, P. H.; Abood, M. E. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol. Pharmacol. 1999, 55, 605-613.
31. GRID v. 22 Molecular Disovery Ltd. (http://www.moldiscovery.com).
32. Huffman, J. W.; Zengin, G.; Wu, M. J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley: J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg. Med. Chem. 2005, 13, 89-112.
33. Vannacci, A.; Giannini, L.; Passani, M. B.; Di Felice, A.; Pierpaoli, S.; Zagli, G.; Fantappiè, O.; Mazzanti, R.; Masini, E.; Mannaioni, P. F. The endocannabinoid 2-Arachidonylglycerol decreases the immunological activation of guinea pig mast cells: involvement of nitric oxide and eicosanoids. J. Pharmacol. Exp. Ther. 2004, 311, 256-264.
34. Unpublished results from our laboratory.
35. Ferrarini, P. L.; Calderone, V.; Cavallini, T.; Manera, C.; Saccomanni, G.; Pani, L.; Ruiu, S.; Gessa, G. L. Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. Bioorg. Med. Chem. 2004, 12, 1921-1933.
36. Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Metters, K. M.; Labelle, M. New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg. Med. Chem. Lett. 1996, 6, 2263-2268.
37. Chatterjee, S.; Hadi, A. S.; Price, B. Regression Analysis of Examples; John Wiley & Sons: New York, 2000.
38. Huffman, J. W.; Szklennik, P. V.; Almond, A.; Bushell, K.; Selley, D. E.; He, H.; Cassidy, M. P.; Wiley: J. L.; Martin, B. R. 1-Pentyl-3- phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 2005, 15, 4110-4113.
39. Montero, C.; Campillo, N. E.; Goya, P.; Páez, J. A. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. Eur. J. Med. Chem. 2005, 40, 75-83.
40. Shim, J. Y.; Welsh, W. J.; Howlett, A. C. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71, 169-189.
41. Xie, X. Q.; Chen, J. Z.; Billings, E. M. 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins 2003, 53, 307-319.
42. Salo, O. M. H.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Järvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem. 2005, 48, 7166-7171.
43. Ballesteros, J. A.; Weinstein, H. W. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 1995, 25, 366-428.
44. 2 Adrenergic receptor activation. J. Biol. Chem. 2002, 277, 40989-40996.
45. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne P. E. The Protein Data Bank. Nucl. Acids Res. 2000, 28, 235-242.
46. Gasteiger, E.; Gattiker, A.; Hoogland, C.; Ivanyi, I.; Appel, R. D.; Bairoch, A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003, 31, 3784-3788.
47. Bramblett, R. D.; Panu, A. M.; Ballesteros, J. A.; Reggio, P. H. Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci. 1995, 56, 1971-1982.
48. McAllister, S. D.; Tao, Q.; Barnett-Norris, J.; Buehner, K.; Hurst, D. P.; Guarnieri, F.; Reggio, P. H.; Nowell Harmon, K. W.; Cabral, G. A.; Abood, M. E. A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem. Pharmacol. 2002, 63, 2121-2136.
49. Barnett-Norris, J.; Hurst, D. P.; Lynch, D. L.; Guarnieri, F.; Makriyannis, A.; Reggio, P. H. Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J. Med. Chem. 2002, 45, 3649-3659.
50. Murphy, J. W.; Kendall, D. A. Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP55940 but not SR 141716A. Biochem. Pharmacol. 2003, 65, 1623-1631.
51. 2 receptor. Eur. J. Pharm. 2000, 401, 17-25.
52. Macromodel ver. 8.5, Schrodinger Inc., 1999.
53. WebLab Viewer Pro 3.7 (Accelrys Inc., San Diego, CA).
54. Gaussian 03, Revision C.02, Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, Jr., J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; and Pople, J. A.; Gaussian, Inc., Wallingford, CT, 2004.
55. Reggio, P. H.; Basu-Dutt, S.; Barnett-Norris, J.; Castro, M. T.; Hurst, D. P.; Seltzman, H. H.; Roche, M. J.; Gilliam, A. F.; Thomas, B. F.; Stevenson, L. A.; Pertwee, R. G.; Abood, M. E. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. J. Med. Chem. 1998, 41, 5177-87.
56. Cuma, M.; Scheiner, S.; Kar, T. Effect of adjoining aromatic ring upon excited-state proton transfer, o-hydroxybenzaldehyde. THEOCHEM 1999, 467, 37-49.
57. Bauschlicher, C. W. A comparison of the accuracy of different functionals. Chem. Phys. Lett. 1995, 246, 40-44.
58. http://www.scripps.edu/∼sanner/python/adt